Cantor Fitzgerald analyst Li Watsek downgraded Oncternal Therapeutics to Neutral from Overweight with an unchanged price target of $1.30 after the company announced the discontinuation of its lead program zilovertamab in mantle-cell lymphoma and chronic lymphocytic leukemia.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ONCT:
- Biotech Alert: Searches spiking for these stocks today
- Oncternal Craters after Halting Two Clinical Studies
- Oncternal Therapeutics downgraded to Hold from Buy at Maxim
- Oncternal Therapeutics price target lowered to $1.30 from $4.00 at Cantor Fitzgerald
- Oncternal Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
